United Therapeutics

PAH / pulmonary disease therapeutics

UTHR · Nasdaq · United States

Share price · UTHR

$577.34+59.07 (+11.40%) 3M

close as of 2026-11-18 · 24h delayed · vol 434K (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when UTHR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 1 Oct 2026+5.4%
  2. 30 Sep 2026+12.5%
  3. 24 Sep 2026-3.5%
  4. 2 Sep 2026-4.0%
  5. 30 Mar 2026+12.5%
  6. 9 Mar 2026+10.7%
  7. 26 Feb 2026-5.9%
  8. 25 Feb 2026+13.0%

Share of unusual movement by asset

For each asset, the share of UTHR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Treprostinil (Tyvaso) (Tyvaso)
events and moves
7shown from 8 days
Ralinepag
events and moves
4shown from 8 days
Assets with fewer than 8 event days, together—39%
Other company news (earnings, financing, releases naming no asset)—22%
Sessions with no dated event—39%

Assets

(7 total)
7Total Assets
6Approved
1Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
Approved
GD2Monoclonal antibody
Neuroblastoma
Tadalafil(Adcirca)
Approved
PDE5Small molecule
Pulmonary Arterial Hypertension
Approved
IP receptor (prostacyclin pathway)Small molecule
Pulmonary Arterial Hypertension
Approved
IP receptor (prostacyclin pathway)Small molecule
Pulmonary Arterial Hypertension
Approved
IP receptor (prostacyclin pathway)Small molecule
Idiopathic Pulmonary FibrosisPulmonary Arterial HypertensionPulmonary Hypertension Associated with Interstitial Lung Disease
Approved
IP receptor (prostacyclin pathway)Small molecule
Idiopathic Pulmonary FibrosisPulmonary Arterial HypertensionPulmonary Hypertension Associated with Interstitial Lung Disease
Phase 3
IP receptor (prostacyclin pathway)Small molecule
Pulmonary Arterial Hypertension

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
RalinepagPhase 3PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases …
Est. primary completion 2026-12 · NCT03683186 · CT.gov ↗
What to watch
2027 (1)
November 2027 (1)
Treprostinil (Tyvaso)Phase 3Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Est. primary completion 2027-11 · NCT05943535 · CT.gov ↗
What to watch
2028 (1)
May 2028 (1)
Treprostinil (Tyvaso)Phase 2Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Est. primary completion 2028-05 · NCT07923591 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
Treprostinil (Tyvaso)Phase 3Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
Est. primary completion 2029-12 · NCT04905693 · CT.gov ↗
What to watch
2034 (1)
September 2034 (1)
Treprostinil (Tyvaso)Phase 2/3Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Est. primary completion 2034-09 · NCT07923526 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(6)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

24 June 2027FDA action dateRalinepagRalinepag PDUFA date
US, FDA · United Therapeutics · Source ↗

Recent

2 September 2026Filing acceptedTreprostinilFDA accepts sNDA for nebulized Tyvaso in idiopathic pulmonary fibrosis
US, FDA · United Therapeutics Corporation · Source ↗
24 August 2026Filing acceptedRalinepagFDA accepts ralinepag NDA
US, FDA · United Therapeutics · Source ↗
June 2026Filing submittedRalinepagRalinepag NDA submitted
US, FDA · United Therapeutics · Source ↗
30 March 2026Topline resultTreprostinilTETON-1 (NCT04708782) Phase 3 of nebulized Tyvaso in IPF met its primary endpoint
United Therapeutics Corporation · Source ↗
2 September 2025Topline resultTreprostinilTETON-2 (NCT05255991) Phase 3 of nebulized Tyvaso in IPF met its primary endpoint
United Therapeutics Corporation · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$833M$279M$1.2B+ $879M short-term inv.—$307M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$783M$146M$1.8B+ $859M short-term inv.—$314M operating cash flowreport ↗
2026-Q1$782M$138M$1.3B+ $874M short-term inv.—$463M operating cash flowreport ↗
2025-Q3$800M$128M$1.3B+ $1.4B short-term inv.—$562M operating cash flowreport ↗
2025-Q2$799M$134M$1.6B+ $1.5B short-term inv.—$192M operating cash flowreport ↗
2025-Q1$794M$149M$1.9B+ $1.4B short-term inv.—$461M operating cash flowreport ↗
2024-Q3$749M$104M$1.6B+ $1.8B short-term inv.—$377M operating cash flowreport ↗
2024-Q2$715M$140M$1.4B+ $1.6B short-term inv.—$232M operating cash flowreport ↗
2024-Q1$678M$104M$1.3B+ $1.5B short-term inv.—$377M operating cash flowreport ↗
2023-Q3$609M$85M$1.1B+ $1.8B short-term inv.—$346M operating cash flowreport ↗
2023-Q2$597M$89M$1.1B+ $1.6B short-term inv.—$106M operating cash flowreport ↗
2023-Q1$507M$83M$1.2B+ $1.7B short-term inv.—$375M operating cash flowreport ↗
2022-Q3$516M$66M$967M+ $1.6B short-term inv.—$259M operating cash flowreport ↗
2022-Q2$467M$94M$795M+ $1.5B short-term inv.—$127M operating cash flowreport ↗
2022-Q1$462M$69M$813M+ $1.5B short-term inv.—$289M operating cash flowreport ↗
2021-Q3$445M$79M$909M+ $1.1B short-term inv.—$186M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$3.2B$550M$1.6B+ $1.4B short-term inv.—$1.6B operating cash flowreport ↗

United Therapeutics reported fiscal 2025 revenue of $3,182.7M, up 10.6% YoY from $2,877.4M, and R&D spend of $550M, up 14.3% YoY from $481M. Cash and equivalents stood at $1,557.1M, with net income of $1,334.7M for the period.

The company highlighted clinical progress, including the TETON 2 phase 3 study of Nebulized Tyvaso in idiopathic pulmonary fibrosis meeting its primary endpoint, with TETON 1 data expected late in the first quarter or early in the second quarter of 2026. Enrollment in the phase 3 ADVANCE OUTCOMES study of ralinepag concluded in June 2025, with topline data also expected around that time. In xenotransplantation, the FDA cleared the EXPAND study IND and the first UKidney transplant occurred in the fourth quarter of 2025, while the EXTEND study IND was cleared in August 2025.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$2.9B$481M$1.7B+ $1.6B short-term inv.—$1.3B operating cash flowreport ↗
2023-FY$2.3B$408M$1.2B+ $1.8B short-term inv.—$978M operating cash flowreport ↗
2022-FY$1.9B$323M$961M+ $1.9B short-term inv.—$803M operating cash flowreport ↗
2021-FY$1.7B$540M$895M+ $1.0B short-term inv.—$598M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($864K), 2939 sales ($1.4B). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-19MAHON PAUL A · EVP & GENERAL COUNSELOption exercise8,300$146.03$1.2MForm 4
2026-11-19MAHON PAUL A · EVP & GENERAL COUNSELOpen-market sale440$554.73$244KForm 4
2026-11-19MAHON PAUL A · EVP & GENERAL COUNSELOpen-market sale1,240$556.07$690KForm 4
2026-11-19MAHON PAUL A · EVP & GENERAL COUNSELOpen-market sale523$557.46$292KForm 4
2026-11-19MAHON PAUL A · EVP & GENERAL COUNSELOpen-market sale378$558.49$211KForm 4
2026-11-19MAHON PAUL A · EVP & GENERAL COUNSELOpen-market sale400$559.50$224KForm 4
2026-11-19MAHON PAUL A · EVP & GENERAL COUNSELOpen-market sale197$560.63$110KForm 4
2026-11-19MAHON PAUL A · EVP & GENERAL COUNSELOpen-market sale300$561.78$169KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 838 reporting institutions held 41.5M shares ($23.3B, 97.4% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.5,399,649$3.2B
2Avoro Capital Advisors LLC2,630,000$1.6B
3WELLINGTON MANAGEMENT GROUP LLP2,264,247$1.3B
4VANGUARD PORTFOLIO MANAGEMENT LLC2,003,742$1.2B
5VANGUARD CAPITAL MANAGEMENT LLC1,957,539$1.2B
6STATE STREET CORP1,843,963$1.1B
7RENAISSANCE TECHNOLOGIES LLC1,787,019$1.1B
8GEODE CAPITAL MANAGEMENT, LLC1,233,029$729.9M
9JANUS HENDERSON GROUP PLC866,930$514.0M
10AQR CAPITAL MANAGEMENT LLC826,226$486.4M
11ASSETMARK, INC616,050$365.3M
12Invesco Ltd.608,367$360.7M
13FMR LLC528,346$313.3M
14DIMENSIONAL FUND ADVISORS LP512,739$304.0M
15DEERFIELD MANAGEMENT COMPANY, L.P.457,000$271.0M